Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses

Despite major advances in first-line treatment, a significant proportion of patients with diffuse large B-cell lymphoma (DLBCL) will experience treatment failure. Prognosis is particularly poor for relapses occurring less than one year after the end of first-line treatment (early relapses/ER) compar...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Broséus, Julien, Chen, Gaili, Hergalant, Sébastien, Ramstein, Gérard, Mounier, Nicolas, Guéant, Jean-Louis, Feugier, Pierre, Gisselbrecht, Christian, Thieblemont, Catherine, Houlgatte, Rémi
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356640/
https://ncbi.nlm.nih.gov/pubmed/27276707
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9793
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars